Exact Sciences

EXAS · NASDAQ

Price unavailable right now.

No price history for this range.

EXAS analyst rating

HoldConsensus of 13 analysts over the last 12 months. 23% rate it a buy.

Strong buy0
Buy3
Hold10
Underperform0
Sell0

12-month price target · 13 analysts

Average $104.35

Low: $78.78
High: $110.25

Upgrades and downgrades

The latest rating actions, newest first

EXAS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Mizuho	Jan 20, 2026	Downgrade	Outperform → Neutral	$85.00 → $105.00	56%
Evercore ISI Group	Jan 5, 2026	Downgrade	Outperform → In-Line	$105.00	52%
Stifel	Nov 28, 2025	Downgrade	Buy → Hold	$80.00 → $105.00	65%
Canaccord Genuity	Nov 25, 2025	Downgrade	Buy → Hold	$85.00 → $105.00	55%
Benchmark	Nov 24, 2025	Downgrade	Buy → Hold	—	59%
Jefferies	Nov 24, 2025	Downgrade	Buy → Hold	$90.00 → $105.00	66%
Wells Fargo	Nov 21, 2025	Downgrade	Overweight → Equal-Weight	$85.00 → $105.00	66%
William Blair	Nov 21, 2025	Downgrade	Outperform → Market Perform	—	50%
Guggenheim	Nov 21, 2025	Downgrade	Buy → Neutral	—	66%
Barclays	Nov 21, 2025	Downgrade	Overweight → Equal-Weight	$77.00 → $105.00	54%

The case for and against

Updated Mar 20, 2026

Bull case

Exact Sciences is poised for continued growth, especially with the anticipated market adoption of its Cologuard test, which is expected to increase from approximately 15% market share to over 40% in the long term. The company has revised its 2025 guidance upward beyond its recent third-quarter performance, driven by strong revenue growth, highlighted by a 22% year-over-year increase in its core screening business. Additionally, the successful launch of the Cancerguard blood test, along with positive Adjusted EBITDA generation, reinforces a promising financial outlook as Exact Sciences aims to triple the number of individuals screened by 2027.

Bear case

Exact Sciences faces several challenges that contribute to a negative outlook on its stock. The company's reliance on promotional marketing for Cologuard, along with a history of net losses, raises concerns about its ability to achieve and sustain GAAP profitability. Additionally, projected revenue estimates for 2027, although potentially conservative, indicate a shortfall from targets, reflecting uncertainty surrounding future sales performance amid anticipated acquisitions and market competition.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.